BioinvestGPT

BioinvestGPT ApS · Research use only

NCT04684914 (HepTcell in Chronic Hepatitis B): BVCT ex-ante prediction vs. reported outcome

On 20 Nov 2023, BioinvestGPT's BVCT predicted technical partial success and commercial failure for this trial. The 27 Mar 2024 readout is classified on the dashboard as True Negative (TN), a correct prediction. Recorded clinical-benefit conclusion: statistically insignificant and commercially insufficient.

Clinical Trial

NCTID
NCT04684914
Drug Name
HepTcell
Drug MoA
HPV-derived peptides
Drug Modality
peptide drug
Drug Class
First-In-Class
Therapeutic Area
Infections
Indication
Chronic Hepatitis B
Human Patients
87
Sponsor
Altimmune
Phase
Phase 2

Prediction of , index 900

Prospective Prediction
Prediction Index
900
Prediction Date
Commercial Prediction
FAILURE (commercially insufficient clinical benefit)
Technical Prediction
partial SUCCESS (statistically maybe significant yet weak clinical benefit)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
128 days in advance
Readout Data Interpretation
terminated due to lack of efficacy
Press Release
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically insignificant and commercially insufficient
Prediction Classification
True Negative (TN)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
Phase 2, Double-blind, Randomized, Placebo-controlled Study of HepTcell (Adjuvanted FP-02.2) as an Immunotherapeutic Vaccine in Treatment-naïve Patients With Inactive Chronic Hepatitis B (CHB)
Phase
Phase 2
Status
Terminated
Enrollment
87
Lead sponsor
Altimmune, Inc.
Conditions
Hepatitis B, Chronic
Interventions
BIOLOGICAL: HepTcell; DRUG: Placebo
Design
Randomized · Parallel · Double
Primary purpose
Treatment
Start
2020-12-26
Primary completion
2024-03-27
Completion
2024-04-17
Results first posted
2025-12-08
Primary outcomes
  • The Proportion of Patients Achieving Virologic Responses (Baseline to Day 169)

NCT04684914 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials